HCPCS Level II code J0882 denotes the administration of darbepoetin alfa, 1 microgram, for patients with end-stage renal disease on dialysis. This biologic injection is a key component of anemia management in the dialysis population and has national relevance because it affects clinical protocols, outpatient dialysis workflows, and payer coverage decisions across public and private plans. Key payers typically included in coverage discussions are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what J0882 represents clinically and operationally, plus what to expect in payer coverage and billing practice. The publication covers benchmark pricing and utilization context where available, relevant payer policy themes, and coding considerations specific to injectable biologic administration in dialysis settings. It also summarizes common billing modifiers and service line implications when data is available. Data not available in the input is noted explicitly where applicable. The focus is national policy and billing context rather than state-specific rules or provider recommendations.